Zynex (NASDAQ:ZYXI) Updates Q3 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its third quarter earnings guidance on Thursday. The company provided EPS guidance of $0.05 for the period, compared to the consensus EPS estimate of $0.16. The company issued revenue guidance of $50.0, compared to the consensus revenue estimate of $60.13 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Analyst Upgrades and Downgrades

ZYXI has been the subject of several research analyst reports. Royal Bank of Canada lowered their price objective on Zynex from $15.00 to $12.00 and set an outperform rating for the company in a report on Friday. HC Wainwright lowered their price target on Zynex from $21.00 to $16.00 and set a buy rating for the company in a report on Friday.

Zynex Stock Performance

Shares of Zynex stock traded down $1.26 during trading hours on Friday, reaching $8.93. The company’s stock had a trading volume of 1,034,596 shares, compared to its average volume of 195,244. The company has a debt-to-equity ratio of 1.76, a quick ratio of 2.87 and a current ratio of 3.58. Zynex has a one year low of $6.88 and a one year high of $13.77. The company’s 50 day simple moving average is $9.55 and its 200 day simple moving average is $11.06. The stock has a market cap of $283.75 million, a P/E ratio of 38.83 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last issued its earnings results on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The business had revenue of $49.88 million during the quarter, compared to the consensus estimate of $51.99 million. Zynex had a return on equity of 16.34% and a net margin of 4.33%. The business’s revenue was up 11.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.09 EPS. As a group, analysts expect that Zynex will post 0.51 EPS for the current fiscal year.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.